Gilead   4Q Revenues: $1.4 billion (+30%)   4Q Earnings: $568.2 million (+41%)   FY Revenues: $5.3 billion (+26%)   FY Earnings: $2.0 billion (+25%)   Comments: Product sales increased 35% to a record $1.4 billion in the quarter and for the year product sales were up 36% to $5.08 billion, driven primarily by Gilead’s antiviral franchise, and growth in sales of Atripla and Truvada. Antiviral product sales were up 35% to $1.3 billion in the quarter and increased 36% to $4.67 billion for ...